Advances in Alzheimer's and Parkinson's Therapies - An AAT-AD/PD Focus Meeting

Advances in Alzheimer Therapy (AAT) - Alzheimer's disease (AD) / Parkinson's disease (PD) Focus Meeting is organized by Kenes Group and will be held during Mar 15 - 18, 2018 at NH Lingotto, Torino, Piedmont, Italy.

The target audience for this medical event is international medical and scientific professionals worldwide engaged in the neurodegeneration field, from basic scientists to clinical investigators, and from established leaders to young upcoming talents.

Course Description :
The Conference will present all the latest breakthroughs in treatment, translational RandD, early diagnosis, drug development and clinical trials in Alzheimer's, Parkinson's and other related neurological disorders.

A central theme will be to further advance innovative strategies in therapy and prevention, clinical trials and diagnostic markers discussed in the sessions and corridors at AD/PD 2017, in order to focus on driving successful collaborations among academia and industry, leading to the development of innovative drugs and ultimately providing for a better future for patients and families affected by neurodegenerative diseases.

Themes :
• ?-Amyloid Diseases
• Tauopathies
• ?-Synucleinopathies
• TDP-43- and C9orf72-Related Diseases
• Vascular Dementia
• Prion Diseases
• Lysosomal and Storage Diseases
• Psychiatric and Epileptic Symptoms
• Patient Care and Support

Topics :
• Disease Mechanisms, Pathophysiology
• Therapeutic Targets, Mechanisms for Treatment
• Drug Development, Clinical Trials
• Imaging, Biomarkers, Diagnostics
• Genetics, Epidemiology
• Cell, Molecular and Systems Biology

Conference Objectives are :
• Address individual needs in compliance with their Continuous Professional Development (CPD) plan.
• Discuss the role of the gut microbiota in Alzheimer's disease.
• Describe current developments in the treatment of Parkinson's and related diseases.
• Evaluate the treatment of Alzheimer in a traditional setting and apply multidimensional care.
• Interpret results of new clinical trials in Alzheimer's and Parkinson's disease.
• Enhance dialogue with clinical investigators and basic scientists, as well as established investigators and young upcoming talents.
• Evaluate the most recent research in in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer's, Parkinson's and other related neurological disorders.
• Apply appropriate preventive strategies in neurodegenerative diseases.

Additional details will be posted as soon as they are available.